Home Featured Page 138

Featured

Latest

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Adapting to the Squeeze: Spending Trends, Slimming Pipelines, M&A and Partnerships...

Psychedelic Investor Pulse Survey – Q4 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment...

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of...

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Small Pharma To Announce Results of SPL026 Phase IIa Trial for...

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial...

Panel: Three Psychedelics Companies that Raised in 2022

EDITOR PICKS

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Adapting to the Squeeze: Spending Trends, Slimming Pipelines, M&A and Partnerships...

Psychedelic Investor Pulse Survey – Q4 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment...

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of...

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Small Pharma To Announce Results of SPL026 Phase IIa Trial for...

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial...

Panel: Three Psychedelics Companies that Raised in 2022

EDITOR PICKS

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY